Exploring new ways to enhance the immune response against cancer cells
Genetic and immunological dissection of coinhibitory crosstalks between human T cells and cancer cells
This study is looking at how your immune cells interact with cancer cells to find new ways to help improve cancer treatments, and we’d love for patients to share their samples or information to help us discover what might work better for some people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11190940 on NIH RePORTER |
What this research studies
This research investigates the interactions between human T cells and cancer cells to identify new checkpoint molecules that could improve cancer immunotherapy. By understanding these interactions, the study aims to uncover mechanisms that may allow certain patients to respond better to existing treatments like checkpoint blockade immunotherapy. The approach involves analyzing genetic and immunological factors that influence how well the immune system can fight cancer. Patients may be involved in providing samples or data to help identify these novel pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer patients, particularly those who have not responded to standard immunotherapy treatments.
Not a fit: Patients with non-cancerous conditions or those who have already achieved remission may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve outcomes for patients who currently do not respond to existing therapies.
How similar studies have performed: Other research has shown promise in identifying novel immune checkpoints, suggesting that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Ogishi, Masato — Stanford University
- Study coordinator: Ogishi, Masato
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.